FDA Reviews New Potential Spinocerebellar Ataxia Drug
The agency accepted a resubmitted application for a drug that could become the first approved treatment for the condition.
Updated on Oct. 22, 2026 in Alzheimer’s
Live Poll
Should the FDA prioritize faster approval for rare disease treatments over strict trial design requirements?
The FDA has accepted a resubmitted drug application for troriluzole, a potential treatment for spinocerebellar ataxia. This development offers hope for the approximately 6,000 patients in North America who currently have no FDA-approved treatment options for the condition.
Why it matters
As the first potential therapy for spinocerebellar ataxia, troriluzole could provide a significant new treatment pathway for patients facing this progressive disease. The FDA is currently reviewing new data to address prior concerns regarding the drug's trial design.
The application follows a previous complete response letter from the FDA in November 2025. While the regulator is now reviewing new supportive analyses, the final determination on the safety and efficacy of the drug remains unresolved.
The players
Biohaven
A pharmaceutical company headquartered in New Haven, Conn., that develops treatments for neurological and neuropsychiatric diseases.
FDA
The federal agency responsible for evaluating the safety and efficacy of new drug applications in the United States.
The details
Troriluzole aims to treat spinocerebellar ataxia by reducing synaptic glutamate levels in the brain. It functions by augmenting excitatory amino acid transporters found on glial cells. This process is intended to limit the excitotoxicity associated with the disease, potentially slowing its progression.
Timeline
• 2023: The FDA issued a refuse to file letter to Biohaven.
• November 2025: The FDA issued a complete response letter regarding the initial application.
• October 22, 2026: Biohaven shares rose 25% following the application acceptance.
• Q1 2027: The FDA has set a user fee goal date for a final decision on the drug.
Health Landscape
Spinocerebellar ataxia currently lacks any FDA-approved standard of care, leaving a significant gap in treatment for patients. This application represents a move toward filling that void through the development of specialized neurological therapies.
Patients and families affected by spinocerebellar ataxia should track the FDA's upcoming advisory committee discussions for further evidence on the drug's potential efficacy. Any questions regarding the applicability of this treatment should be discussed with a neurologist specializing in movement disorders.
The takeaway
The FDA's acceptance of the resubmitted application is a positive signal for the potential availability of the first treatment for spinocerebellar ataxia. Patients should monitor for updates in early 2027 and maintain ongoing conversations with their medical care team regarding disease management.
What happens next
The FDA plans to convene an advisory committee meeting to discuss the drug prior to the user fee goal date in the first quarter of 2027.
Further reading
For more information on the latest research in the field, explore our Alzheimer’s section.
Live Poll
Should the FDA prioritize faster approval for rare disease treatments over strict trial design requirements?
